The amyloidogenic potential and behavioral correlates of stress
Tóm tắt
Từ khóa
Tài liệu tham khảo
Guillozet AL, Weintraub S, Mash DC, Mesulam MM . Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 2003; 60: 729–736.
Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosc 2005; 8: 79–84.
Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM et al. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis 2005; 20: 187–198.
Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P et al. Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci 2005; 25: 11061–11070.
Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572–580.
Olariu A, Tran MH, Yamada K, Mizuno M, Hefco V, Nabeshima T . Memory deficits and increased emotionality induced by β-amyloid (25–35) are correlated with the reduced acetylcholine release and altered phorbol dibutyrate binding in the hippocampus. J Neural Transm 2001; 108: 1065–1079.
Bayer TA, Wirths O, Majtenyi K, Hartmann T, Multhaup G, Beyreuther K et al. Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol 2001; 11: 1–11.
Lorenzo A, Yankner BA . Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 1994; 91: 12243–12247.
Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, O’Hare E et al. Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 1998; 18: 2161–2173.
Yankner BA, Dawes LR, Fisher S, Villa-Komaroff L, Oster-Granite ML, Neve RL . Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 1989; 245: 417–420.
Oster-Granite ML, McPhie DL, Greenan J, Neve RL . Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. J Neurosci 1996; 16: 6732–6741.
Nalbantoglu J, Tirado-Santiago G, Lahsaini A, Poirier J, Goncalves O, Verge G et al. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature 1997; 387: 500–505.
Berger-Sweeney J, McPhie DL, Arters JA, Greenan J, Oster-Granite ML, Neve RL . Impairments in learning and memory accompanied by neurodegeneration in mice transgenic for the carboxyl-terminus of the amyloid precursor protein. Mol Brain Res 1999; 66: 150–162.
Lorenzo A, Yuan M, Zhang Z, Paganetti PA, Sturchler-Pierrat C, Staufenbiel M et al. Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. Nat Neurosci 2000; 3: 460–464.
Heredia L, Lin R, Vigo FS, Kedikian G, Busciglio J, Lorenzo A . Deposition of amyloid fibrils promotes cell-surface accumulation of amyloid beta precursor protein. Neurobiol Dis 2004; 16: 617–629.
Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I . Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging 1997; 18: 285–289.
Elgh E, Lindqvist Astot A, Fagerlund M, Eriksson S, Olsson T, Nasman B . Cognitive dysfunction, hippocampal atrophy and glucocorticoid feedback in Alzheimer's disease. Biol Psychiatry 2006; 59: 155–161.
Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM . Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci 2006; 26: 9047–9056.
Jeong YH, Park CH, Yoo J, Shin KY, Ahn SM, Kim HS et al. Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APPV717I-CT100 transgenic mice, an Alzheimer's disease model. FASEB J 2006; 20: 729–731.
Lupien SJ, Fiocco A, Wan N, Maheu F, Lord C, Schramek T et al. Stress hormones and human memory function across the lifespan. Psychoneuroendocrinology 2005; 30: 225–242.
Cerqueira JJ, Pego JM, Taipa R, Bessa JM, Almeida OF, Sousa N . Morphological correlates of corticosteroid-induced changes in prefrontal cortex-dependent behaviors. J Neurosci 2005; 25: 7792–7800.
Sousa N, Almeida OFX . Corticosteroids: sculptors of the hippocampal formation. Rev Neurosci 2002; 13: 59–84.
Cerqueira JJ, Taipa R, Almeida OFX, Sousa N . Specific configuration of dendritic degeneration in pyramidal neurons of the medial prefrontal cortex induced by differing corticosteroid regimen. Cereb Cortex 2006; 17: 1998–2006.
Phelps EA . Emotion and cognition: insights from studies of the human amygdala. Annu Rev Psychol 2006; 57: 27–53.
Ownby RL, Harwood DG, Barker WW, Duara R . Predictors of anxiety in patients with Alzheimer's disease. Depress Anxiety 2000; 11: 38–42.
Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D . Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006; 63: 530–538.
Sousa N, Almeida OFX, Holsboer F, Paula-Barbosa MM, Madeira MD . Maintenance of hippocampal cell numbers in young and aged rats submitted to chronic unpredictable stress. Comparison with the effects of corticosterone treatment. Stress 1998; 2: 237–249.
Paxinos G, Watson C . The Rat Brain in Stereotaxic Coordinates, 4th edn. Academic Press: San Diego, 1998.
Solà C, Mengod G, Probst A, Palacios KM . Differential regional and cellular distribution of â-amyloid precursor RNAs containing and lacking the Kunitz protease inhibitor domain in the brain of human, rat and mouse. Neuroscience 1993; 53: 267–295.
Panegyres PK . The effects of excitotoxicity on the expression of the amyloid precursor protein gene in the brain and its modulation by neuroprotective agents. J Neural Transm 1998; 105: 463–478.
Ni Y, Zhao X, Bao G, Zou L, Teng L, Wang Z et al. Activation of beta(2)-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. Nat Med 2007; 12: 1390–1396.
Stephan A, Phillips AG . A case for a non-transgenic animal model of Alzheimer's disease. Genes Brain Behav 2005; 4: 157–172.
Davis-Salinas J, Saporito-Irwin SM, Cotman CW, Van Nostrand WE . Amyloid beta-protein induces its own production in cultured degenerating cerebrovascular smooth muscle cells. J Neurochem 1995; 65: 931–934.
Frautschy SA, Yang F, Calderon L, Cole GM . Rodent models of Alzheimer's disease: rat A beta infusion approaches to amyloid deposits. Neurobiol Aging 1996; 17: 311–321.
Magarinos AM, Verdugo JM, McEwen BS . Chronic stress alters synaptic terminal structure in hippocampus. Proc Natl Acad Sci USA 1997; 94: 14002–14008.
Lupien SJ, de Leon M, de Santi S, Convit A, Tarshish C, Nair N et al. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci 1998; 1: 69–73.
Sousa N, Paula-Barbosa MM, Almeida OFX . Ligand and subfield specificity of corticoid-induced neuronal loss in the rat hippocampal formation. Neuroscience 1999; 89: 1079–1087.
Wellman CL . Dendritic reorganization in pyramidal neurons in medial prefrontal cortex after chronic corticosterone administration. J Neurobiol 2001; 49: 245–253.
Cerqueira JJ, Catania C, Sotiropoulos I, Schubert M, Kalisch R, Almeida OFX et al. Corticosteroid status influences the volume of the rat cingulate cortex—a magnetic resonance imaging study. J Psychiatr Res 2005; 39: 451–460.
Radley JJ, Morrison JH . Repeated stress and structural plasticity in the brain. Ageing Res Rev 2005; 4: 271–287.
McEwen BS, De Kloet ER, Rostene W . Adrenal steroid receptors and actions in the nervous system. Physiol Rev 1986; 66: 1121–1188.
Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991; 82: 239–259.
Islam A, Kalaria RN, Winblad B, Adem A . Enhanced localization of amyloid beta precursor protein in the rat hippocampus following long-term adrenalectomy. Brain Res 1998; 806: 108–112.
Budas G, Coughlan CM, Seckl JR, Breen KC . The effect of corticosteroids on amyloid beta precursor protein/amyloid precursor-like protein expression and processing in vivo. Neurosci Lett 1999; 276: 61–64.
Sambamurti K, Kinsey R, Maloney B, Ge YW, Lahiri DK . Gene structure and organization of the human beta-secretase (BACE) promoter. FASEB J 2004; 18: 1034–1036.
Haass C . Take five—BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J 2004; 23: 483–488.
Johnston JA, Liu WW, Todd SA, Coulson DT, Murphy S, Irvine GB et al. Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer's disease. Biochem Soc Trans 2005; 33: 1096–1100.
Li Y, Zhou W, Tong Y, He G, Song W . Control of APP processing and Abeta generation level by BACE1 enzymatic activity and transcription. FASEB J 2006; 20: 285–292.
Yang DS, Tandon A, Chen F, Yu G, Yu H, Arawaka S et al. Mature glycosylation and trafficking of nicastrin modulate its binding to presenilins. J Biol Chem 2002; 277: 28135–28142.
Herreman A, Van Gassen G, Bentahir M, Nyabi O, Craessaerts K, Mueller U et al. γ-secretase activity requires the presenilin-dependent trafficking of nicastrin through the Golgi apparatus but not its complex glycosylation. J Cell Sci 2003; 116: 1127–1136.
Shah S, Lee SF, Tabuchi K, Hao YH, Yu C, LaPlant Q et al. Nicastrin functions as a gamma-secretase-substrate receptor. Cell 2005; 122: 435–447.
Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BA . Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat Med 1998; 4: 827–831.
Starkman MN, Giordani B, Berent S, Schork MA, Schteingart DE . Elevated cortisol levels in Cushing's disease are associated with cognitive decrements. Psychosom Med 2001; 63: 985–993.
Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999; 155: 853–862.
Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007; 68: 501–508.
McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46: 860–866.
Braak H, Braak E . Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging 1997; 18(Suppl 4): S85–S88.
Swanwick GR, Kirby M, Bruce I, Buggy F, Coen RF, Coakley D et al. Hypothalamic–pituitary–adrenal axis dysfunction in Alzheimer's disease: lack of association between longitudinal and cross-sectional findings. Am J Psychiatry 1998; 155: 286–289.
Behl C, Lezoualch F, Trapp T, Widmann M, Skutella T, Holsboer F . Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro. Endocrinology 1997; 138: 101–106.
Sapolsky RM . The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 2000; 48: 755–765.
Grossberg GT . Diagnosis and treatment of Alzheimer's disease. J Clin Psychiatry 2003; 64(Suppl 9): S3–S6.
Tatsch MF, Bottino CM, Azevedo D, Hototian SR, Moscoso MA, Folquitto JC et al. Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a community-based sample in Brazil: prevalence and relationship with dementia severity. Am J Geriatr Psychiatry 2006; 14: 438–445.
in ‘t Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515–1521.